NASDAQ:ANIX

Anixa Biosciences Q4 2025 Earnings Results & Report

Anixa Biosciences logo
$2.44 -0.16 (-6.15%)
As of 04:00 PM Eastern

Anixa Biosciences met analyst earnings expectations in its Q4 2025 results, released January 12, 2026. The company reported EPS of -$0.09 versus the -$0.09 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Anixa Biosciences EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.09
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Anixa Biosciences' Q4 2026 earnings is estimated for Monday, January 11, 2027, based on past reporting schedules, with a conference call scheduled on Tuesday, January 12, 2027 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Anixa Biosciences Q4 2025 Earnings FAQ

Anixa Biosciences (NASDAQ:ANIX) reported earnings of -$0.09 per share for Q4 2025, matching the consensus estimate of -$0.09. The report was announced on Monday, January 12, 2026.

Anixa Biosciences' next earnings date is estimated for Monday, January 11, 2027. MarketBeat tracks confirmed and estimated earnings dates for Anixa Biosciences on the company's earnings history page.

Anixa Biosciences Earnings Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), Inc. is a U.S.-based biotechnology company focused on developing cancer immunotherapies. Its research programs include a CAR T-cell therapy designed to target ovarian cancer and cancer vaccine candidates developed with research partners.

The company’s ovarian cancer program uses T cells engineered to recognize follicle-stimulating hormone receptors on cancer cells and is being developed in collaboration with Moffitt Cancer Center. Anixa is also working with Cleveland Clinic on a breast cancer vaccine program intended to stimulate an immune response against cancer-related targets.

Anixa has also pursued cancer-detection technologies through its Cchek platform. The company is led by Amit Kumar, who serves as chairman and chief executive officer.

View Anixa Biosciences Profile